12 Month Price Forecast For GNLX
Distance to GNLX Price Forecasts
GNLX Price Momentum
🤔 Considering Genelux (GNLX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 12:59 PM UTC
GNLX Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, GNLX has a consensus that is bullish. The median price target is $19.00, with forecasts ranging from $8.00 to $30.00. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With GNLX currently trading at $2.52, the median price forecast suggests a 654.0% upside. The most optimistic forecast comes from Emily Bodnar at HC Wainwright & Co., projecting a 1,090.5% upside, while Kelsey Goodwin at Guggenheim provides the most conservative target, suggesting a 217.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GNLX Analyst Consensus
GNLX Price Target Range
Latest GNLX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GNLX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $30.00 |
| Oct 29, 2024 | Guggenheim | Kelsey Goodwin | Buy | Initiates | $8.00 |
| Aug 27, 2024 | Roth MKM | Benjamin Paluch | Buy | Initiates | $10.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $32.00 |
| Jun 3, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $25.00 |
| May 31, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Maintains | $25.00 |
| May 13, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $32.00 |
| Apr 3, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $30.00 |
| Apr 2, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $32.00 |
| Nov 27, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Initiates | $35.00 |
| Nov 24, 2023 | Benchmark | Bruce Jackson | Speculative Buy | Maintains | $30.00 |
| Sep 12, 2023 | Maxim Group | Jason McCarthy | Buy | Initiates | $40.00 |
| Jun 9, 2023 | Benchmark | Bruce Jackson | Speculative Buy | Maintains | $38.00 |
| May 18, 2023 | Brookline Capital | Kemp Dolliver | Hold | Initiates | $25.00 |
| Feb 15, 2023 | Benchmark | Bruce Jackson | Speculative Buy | Initiates | $10.00 |
GENELUX CORPORATION (GNLX) Financial Data
GENELUX CORPORATION has a market capitalization of $94.29M with a P/E ratio of -2.2x. The company generates $8,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -341,437.5% and return on equity of -88.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
GENELUX CORPORATION (GNLX) Company Overview
About GENELUX CORPORATION
Develops oncolytic viral immunotherapies for cancer.
Genelux Corporation operates as a clinical-stage biopharmaceutical company, focusing on creating innovative treatments for aggressive solid tumors through oncolytic viral immunotherapies. The company generates revenue through product development and potential licensing agreements, as evidenced by its partnership with ELIAS Animal Health for its animal health product candidate.
Founded in 2001 and based in Westlake Village, California, Genelux is advancing its lead product, Olvi-Vec, aimed at treating ovarian and non-small cell lung cancers, while also exploring therapies for pancreatic cancer. As a clinical-stage entity, its success hinges on upcoming clinical trial results and regulatory approvals.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
24
CEO
Mr. Thomas Zindrick J.D.
Country
United States
IPO Year
N/A
Website
www.genelux.comGENELUX CORPORATION (GNLX) Latest News & Analysis
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
1 month agoGenelux Corporation (NASDAQ: GNLX) CEO Thomas Zindrick will discuss clinical programs and milestones at the Guggenheim Healthcare Innovation Conference on November 11-13, 2024, in Boston.
Genelux's CEO will outline key clinical programs and milestones at a prominent healthcare conference, signaling potential growth and investment opportunities in the immuno-oncology sector.
Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point
1 month agoTopline results from the phase 3 OnPrime/GOG-3076 study of Olvi-Vec for platinum-resistant ovarian cancer are expected in H2 2025. Interim data for lung cancer trials is due mid-2025 and H2 2024.
The timeline for Olvi-Vec trial results affects potential market entry and revenue projections for the drug, influencing investor sentiment and stock valuations in biotech firms involved.
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
1 month agoThe VIRO-25 trial will evaluate olvimulogene nanivacirepvec (Olvi-Vec) combined with platinum-doublet and immune checkpoint inhibitors versus docetaxel for recurrent non-small cell lung cancer.
The VIRO-25 trial results could impact the stock performance of companies involved in lung cancer treatments, influencing market sentiment and investment decisions in biotech.
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
2 months agoGenelux Corporation (NASDAQ: GNLX) CEO Thomas Zindrick will present at the 2024 Maxim Healthcare Virtual Summit from October 15-17, 2024.
Genelux's CEO participation in a prominent healthcare summit indicates active engagement and visibility, potentially enhancing investor confidence and interest in the company's developments.
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
3 months agoGenelux Corporation (NASDAQ: GNLX) will present its clinical-stage programs and milestones at the H.C. Wainwright Global Healthcare Conference on September 9-11, 2024.
Genelux's presentation at a major healthcare conference highlights its clinical progress and upcoming milestones, which could influence investor sentiment and stock performance.
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
3 months agoGenelux Corporation (NASDAQ: GNLX) reported its second-quarter 2024 financial results and shared general business updates on August 14, 2024.
Genelux Corporation's financial results and business updates can indicate its growth potential and market viability, impacting investor sentiment and stock performance.
Frequently Asked Questions About GNLX Stock
What is GENELUX CORPORATION's (GNLX) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, GENELUX CORPORATION (GNLX) has a median price target of $19.00. The highest price target is $30.00 and the lowest is $8.00.
Is GNLX stock a good investment in 2025?
According to current analyst ratings, GNLX has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for GNLX stock?
Wall Street analysts predict GNLX stock could reach $19.00 in the next 12 months. This represents a 654.0% increase from the current price of $2.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is GENELUX CORPORATION's business model?
Genelux Corporation operates as a clinical-stage biopharmaceutical company, focusing on creating innovative treatments for aggressive solid tumors through oncolytic viral immunotherapies. The company generates revenue through product development and potential licensing agreements, as evidenced by its partnership with ELIAS Animal Health for its animal health product candidate.
What is the highest forecasted price for GNLX GENELUX CORPORATION?
The highest price target for GNLX is $30.00 from Emily Bodnar at HC Wainwright & Co., which represents a 1,090.5% increase from the current price of $2.52.
What is the lowest forecasted price for GNLX GENELUX CORPORATION?
The lowest price target for GNLX is $8.00 from Kelsey Goodwin at Guggenheim, which represents a 217.5% increase from the current price of $2.52.
What is the overall GNLX consensus from analysts for GENELUX CORPORATION?
The overall analyst consensus for GNLX is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $19.00.
How accurate are GNLX stock price projections?
Stock price projections, including those for GENELUX CORPORATION, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
